Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.
This study demonstrates, through a combination of stringent screening methods and thorough validation, that it is possible to identify transmembrane proteins preferentially expressed in primary breast tumour cells. mRNA was extracted from tumour cells isolated from invasive breast cancers and it was then subtracted against normal breast tissue mRNA prior to the generation of a signal sequence-trap library. Screening of the library identified 31 positive clones encoding 12 cell-surface and 12 secreted proteins. The expression of a subset of transmembrane genes was then interrogated using a high-throughput method (tissue microarray) coupled with cutting-edge in situ techniques in a large cohort of patients who had undergone uniform adjuvant chemotherapy. Expression of CD98 heavy chain (CD98HC) and low-level expression of the insulin-like growth factor 2 receptor/mannose-6-phosphate receptor (IGF2R/M6PR) correlated with poor patient prognosis in the whole cohort. Expression of bradykinin receptor B1 (BDKRB1) and testis enhanced gene transcript (TEGT) correlated with good prognosis in woman with oestrogen receptor (ER)-negative breast tumours. These results indicate that this combined approach of isolating primary tumour cells, generating a library to specifically isolate signal-sequence-containing transcripts, and in situ hybridization on tissue microarrays successfully identified novel prognostic markers (BDKRB1, CD98hc, and TEGT) and potential transmembrane therapeutic targets (CD98hc) in breast cancer.
Esseghir
S
S
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
Reis-Filho
J S
JS
Kennedy
A
A
James
M
M
O'Hare
M J
MJ
Jeffery
R
R
Poulsom
R
R
Isacke
C M
CM
D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D027282:Fusion Regulatory Protein 1, Heavy Chain / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics; D008565:Membrane Proteins / Q000235:genetics; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000235:genetics*; D011379:Prognosis; D011506:Proteins / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D043783:Receptor, Bradykinin B1 / Q000235:genetics; D017527:Receptor, IGF Type 2 / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D046888:Tissue Array Analysis / Q000379:methods; D014158:Transcription, Genetic / Q000235:genetics*
D051017:Apoptosis Regulatory Proteins; D014408:Biomarkers, Tumor; D027282:Fusion Regulatory Protein 1, Heavy Chain; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D011506:Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D043783:Receptor, Bradykinin B1; D017527:Receptor, IGF Type 2; D011960:Receptors, Estrogen; C484209:TMBIM6 protein, human; D018799:Intercellular Adhesion Molecule-1